FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2500843669> ?p ?o ?g. }

• W2500843669 endingPage "54095" @default.
• W2500843669 startingPage "54082" @default.
• W2500843669 abstract "// Hadjer Abdelouahab 1, 2, 3, 4 , Yanyan Zhang 1, 3, 4 , Monika Wittner 1, 3, 4 , Shinya Oishi 6 , Nobutaka Fujii 6 , Rodolphe Besancenot 1, 3, 4 , Isabelle Plo 1, 3, 4, 7, 8 , Vincent Ribrag 1, 3, 4 , Eric Solary 1, 3, 4 , William Vainchenker 1, 3, 4, 8 , Giovanni Barosi 5 and Fawzia Louache 1, 2, 3, 4 1 INSERM, UMR 1170, Gustave Roussy, Villejuif, France 2 University Paris Diderot, Paris, France 3 University Paris-Sud 11, Villejuif, France 4 Gustave Roussy, Villejuif, France 5 Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy 6 Kyoto University, Graduate School of Pharmaceutical Sciences, Kyoto, Japan 7 Equipe labellisée Ligue Nationale contre le Cancer, UMR 1170, Institut Gustave Roussy, Villejuif, France 8 Grex, Laboratoire d’Excellence, Paris, France Correspondence to: Fawzia Louache, email: fawl@igr.fr Keywords: JAK2 inhibitors, CXCR4, hematopoiesis Received: January 27, 2016     Accepted: June 17, 2016     Published: July 22, 2016 ABSTRACT JAK2 activation is the driver mechanism in BCR-ABL- negative myeloproliferative neoplasms (MPN). These diseases are characterized by an abnormal retention of hematopoietic stem cells within the bone marrow microenvironment and their increased trafficking to extramedullary sites. The CXCL12/CXCR4 axis plays a central role in hematopoietic stem cell/ progenitor trafficking and retention in hematopoietic sites. The present study explores the crosstalk between JAK2 and CXCL12/CXCR4 signaling pathways in MPN. We show that JAK2, activated by either MPL-W515L expression or cytokine stimulation, cooperates with CXCL12/CXCR4 signaling to increase the chemotactic response of human cell lines and primary CD34 + cells through an increased phosphatidylinositol-3-kinase (PI3K) signaling. Accordingly, primary myelofibrosis (MF) patient cells demonstrate an increased CXCL12-induced chemotaxis when compared to controls. JAK2 inhibition by knock down or chemical inhibitors decreases this effect in MPL-W515L expressing cell lines and reduces the CXCL12/CXCR4 signaling in some patient primary cells. Taken together, these data indicate that CXCL12/CXCR4 pathway is overactivated in MF patients by oncogenic JAK2 that maintains high PI3K signaling over the threshold required for CXCR4 activation. These results suggest that inhibition of this crosstalk may contribute to the therapeutic effects of JAK2 inhibitors." @default.
• W2500843669 created "2016-08-23" @default.
• W2500843669 creator A5000559973 @default.
• W2500843669 creator A5004745746 @default.
• W2500843669 creator A5023810956 @default.
• W2500843669 creator A5030886151 @default.
• W2500843669 creator A5031789027 @default.
• W2500843669 creator A5032462496 @default.
• W2500843669 creator A5044939434 @default.
• W2500843669 creator A5050114328 @default.
• W2500843669 creator A5065647772 @default.
• W2500843669 creator A5066007350 @default.
• W2500843669 creator A5077897116 @default.
• W2500843669 creator A5089433535 @default.
• W2500843669 date "2016-07-22" @default.
• W2500843669 modified "2023-10-17" @default.
• W2500843669 title "CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner" @default.
• W2500843669 cites W1510842546 @default.
• W2500843669 cites W1536989454 @default.
• W2500843669 cites W1968381020 @default.
• W2500843669 cites W1970327341 @default.
• W2500843669 cites W1972001907 @default.
• W2500843669 cites W1985902169 @default.
• W2500843669 cites W1986560933 @default.
• W2500843669 cites W1987470267 @default.
• W2500843669 cites W1987930421 @default.
• W2500843669 cites W1988879621 @default.
• W2500843669 cites W1995159861 @default.
• W2500843669 cites W2004289105 @default.
• W2500843669 cites W2005718040 @default.
• W2500843669 cites W2012056552 @default.
• W2500843669 cites W2015506962 @default.
• W2500843669 cites W2015535501 @default.
• W2500843669 cites W2031513730 @default.
• W2500843669 cites W2043993681 @default.
• W2500843669 cites W2046567666 @default.
• W2500843669 cites W2048866300 @default.
• W2500843669 cites W2049145190 @default.
• W2500843669 cites W2057360098 @default.
• W2500843669 cites W2060564335 @default.
• W2500843669 cites W2064453268 @default.
• W2500843669 cites W2067047023 @default.
• W2500843669 cites W2074849382 @default.
• W2500843669 cites W2075033192 @default.
• W2500843669 cites W2079961239 @default.
• W2500843669 cites W2085603059 @default.
• W2500843669 cites W2099604050 @default.
• W2500843669 cites W2106609638 @default.
• W2500843669 cites W2109999727 @default.
• W2500843669 cites W2110190127 @default.
• W2500843669 cites W2113062534 @default.
• W2500843669 cites W2113472355 @default.
• W2500843669 cites W2117431306 @default.
• W2500843669 cites W2117993411 @default.
• W2500843669 cites W2119374469 @default.
• W2500843669 cites W2121497524 @default.
• W2500843669 cites W2134540087 @default.
• W2500843669 cites W2138709799 @default.
• W2500843669 cites W2144664431 @default.
• W2500843669 cites W2157694607 @default.
• W2500843669 cites W2158612499 @default.
• W2500843669 cites W2164845217 @default.
• W2500843669 cites W2169912468 @default.
• W2500843669 cites W2177185177 @default.
• W2500843669 cites W2181745840 @default.
• W2500843669 doi "https://doi.org/10.18632/oncotarget.10789" @default.
• W2500843669 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5589564" @default.
• W2500843669 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28903325" @default.
• W2500843669 hasPublicationYear "2016" @default.
• W2500843669 type Work @default.
• W2500843669 sameAs 2500843669 @default.
• W2500843669 citedByCount "23" @default.
• W2500843669 countsByYear W25008436692017 @default.
• W2500843669 countsByYear W25008436692018 @default.
• W2500843669 countsByYear W25008436692019 @default.
• W2500843669 countsByYear W25008436692020 @default.
• W2500843669 countsByYear W25008436692021 @default.
• W2500843669 countsByYear W25008436692022 @default.
• W2500843669 countsByYear W25008436692023 @default.
• W2500843669 crossrefType "journal-article" @default.
• W2500843669 hasAuthorship W2500843669A5000559973 @default.
• W2500843669 hasAuthorship W2500843669A5004745746 @default.
• W2500843669 hasAuthorship W2500843669A5023810956 @default.
• W2500843669 hasAuthorship W2500843669A5030886151 @default.
• W2500843669 hasAuthorship W2500843669A5031789027 @default.
• W2500843669 hasAuthorship W2500843669A5032462496 @default.
• W2500843669 hasAuthorship W2500843669A5044939434 @default.
• W2500843669 hasAuthorship W2500843669A5050114328 @default.
• W2500843669 hasAuthorship W2500843669A5065647772 @default.
• W2500843669 hasAuthorship W2500843669A5066007350 @default.
• W2500843669 hasAuthorship W2500843669A5077897116 @default.
• W2500843669 hasAuthorship W2500843669A5089433535 @default.
• W2500843669 hasBestOaLocation W25008436691 @default.
• W2500843669 hasConcept C126322002 @default.
• W2500843669 hasConcept C129470790 @default.
• W2500843669 hasConcept C13373296 @default.
• W2500843669 hasConcept C170493617 @default.
• W2500843669 hasConcept C28328180 @default.

• next